Analysts forecast that Veru Inc. (NASDAQ:VERU) will announce earnings per share (EPS) of ($0.03) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Veru’s earnings, with estimates ranging from ($0.04) to ($0.02). Veru posted earnings of ($0.01) per share during the same quarter last year, which suggests a negative year over year growth rate of 200%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, May 12th.
According to Zacks, analysts expect that Veru will report full year earnings of $0.01 per share for the current financial year, with EPS estimates ranging from ($0.09) to $0.09. For the next financial year, analysts forecast that the firm will post earnings of ($0.37) per share, with EPS estimates ranging from ($0.58) to ($0.14). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Veru.
Veru (NASDAQ:VERU) last released its quarterly earnings results on Wednesday, February 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. Veru had a negative return on equity of 23.72% and a negative net margin of 44.55%. The company had revenue of $14.62 million during the quarter, compared to analysts’ expectations of $10.63 million.
A number of analysts have commented on the stock. TheStreet downgraded shares of Veru from a “b-” rating to a “c” rating in a research report on Monday, March 29th. Jefferies Financial Group began coverage on Veru in a research report on Monday. They issued a “buy” rating and a $19.00 target price for the company. Oppenheimer lifted their price target on Veru from $19.00 to $24.00 in a research report on Thursday, February 11th. Zacks Investment Research raised Veru from a “sell” rating to a “hold” rating in a research note on Thursday, February 18th. Finally, HC Wainwright decreased their target price on Veru from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Wednesday, March 3rd. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $17.13.
VERU traded down $0.23 on Friday, reaching $9.01. The company had a trading volume of 741,911 shares, compared to its average volume of 3,631,738. The company has a market capitalization of $647.93 million, a P/E ratio of -32.07 and a beta of 0.71. The company has a fifty day moving average of $11.95 and a 200-day moving average of $8.56. Veru has a one year low of $2.30 and a one year high of $24.57.
In other Veru news, CEO Mitchell Shuster Steiner sold 20,000 shares of the company’s stock in a transaction on Friday, February 12th. The stock was sold at an average price of $20.88, for a total value of $417,600.00. Following the transaction, the chief executive officer now owns 7,184,767 shares of the company’s stock, valued at $150,017,934.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 26.10% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of VERU. Advisory Services Network LLC lifted its stake in Veru by 10.3% during the fourth quarter. Advisory Services Network LLC now owns 8,000 shares of the company’s stock valued at $69,000 after buying an additional 750 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Veru by 2.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 34,169 shares of the company’s stock valued at $296,000 after acquiring an additional 800 shares during the period. Creative Planning lifted its position in shares of Veru by 18.2% in the 4th quarter. Creative Planning now owns 13,020 shares of the company’s stock valued at $113,000 after acquiring an additional 2,001 shares in the last quarter. Panagora Asset Management Inc. boosted its stake in Veru by 462.6% in the 4th quarter. Panagora Asset Management Inc. now owns 3,308 shares of the company’s stock worth $29,000 after purchasing an additional 2,720 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in Veru by 9.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 35,871 shares of the company’s stock worth $310,000 after purchasing an additional 3,153 shares in the last quarter. Hedge funds and other institutional investors own 23.32% of the company’s stock.
Veru Company Profile
Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.
Further Reading: How a Strangle Strategy is different from a Straddle Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com